PL374224A1 - (Imidazol-1-ilometylo) pirydazyna jako bloker receptora NMDA - Google Patents

(Imidazol-1-ilometylo) pirydazyna jako bloker receptora NMDA

Info

Publication number
PL374224A1
PL374224A1 PL03374224A PL37422403A PL374224A1 PL 374224 A1 PL374224 A1 PL 374224A1 PL 03374224 A PL03374224 A PL 03374224A PL 37422403 A PL37422403 A PL 37422403A PL 374224 A1 PL374224 A1 PL 374224A1
Authority
PL
Poland
Prior art keywords
pyridazine
imidazol
methyl
nmda receptor
receptor blocker
Prior art date
Application number
PL03374224A
Other languages
English (en)
Other versions
PL211340B1 (pl
Inventor
Bernd Buettelmann
Neidhart Marie-Paule Heitz
Georg Jaeschke
Emmanuel Pinard
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL374224A1 publication Critical patent/PL374224A1/pl
Publication of PL211340B1 publication Critical patent/PL211340B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL374224A 2002-05-16 2003-05-16 Pochodne (imidazol-1-ilometylo)pirydazyny, lek zawierający te pochodne, sposób wytwarzania i zastosowanie tych pochodnych PL211340B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02010217 2002-05-16

Publications (2)

Publication Number Publication Date
PL374224A1 true PL374224A1 (pl) 2005-10-03
PL211340B1 PL211340B1 (pl) 2012-05-31

Family

ID=29433072

Family Applications (1)

Application Number Title Priority Date Filing Date
PL374224A PL211340B1 (pl) 2002-05-16 2003-05-16 Pochodne (imidazol-1-ilometylo)pirydazyny, lek zawierający te pochodne, sposób wytwarzania i zastosowanie tych pochodnych

Country Status (30)

Country Link
US (1) US7005432B2 (pl)
EP (1) EP1506190B1 (pl)
JP (1) JP4267569B2 (pl)
KR (1) KR100632868B1 (pl)
CN (1) CN1312151C (pl)
AR (1) AR040010A1 (pl)
AT (1) ATE329912T1 (pl)
AU (1) AU2003242542B2 (pl)
BR (1) BR0311177A (pl)
CA (1) CA2485926C (pl)
CL (1) CL2004001251A1 (pl)
CY (1) CY1105159T1 (pl)
DE (1) DE60306152T2 (pl)
DK (1) DK1506190T3 (pl)
ES (1) ES2265581T3 (pl)
HR (1) HRP20041060B1 (pl)
IL (1) IL164922A (pl)
MA (1) MA27117A1 (pl)
ME (1) MEP76708A (pl)
MX (1) MXPA04011253A (pl)
NO (1) NO329605B1 (pl)
NZ (1) NZ536310A (pl)
PL (1) PL211340B1 (pl)
PT (1) PT1506190E (pl)
RS (1) RS51200B (pl)
RU (1) RU2317294C2 (pl)
SI (1) SI1506190T1 (pl)
TN (1) TNSN04224A1 (pl)
WO (1) WO2003097637A1 (pl)
ZA (1) ZA200408789B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
EP1888706B1 (de) * 2005-05-03 2017-03-01 Merck Patent GmbH Organische elektrolumineszenzvorrichtung und in deren herstellung verwendete boronsäure- und borinsäure-derivate
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
JP5315710B2 (ja) * 2008-02-07 2013-10-16 セントラル硝子株式会社 １−ブロモ−３−フルオロ−５−ジフルオロメチルベンゼンの製造方法
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
MX2010009649A (es) * 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
AU2010211050B2 (en) 2009-02-05 2016-05-12 Takeda Pharmaceutical Company Limited Pyridazinone compounds
EP2602255B1 (en) * 2010-08-04 2017-04-26 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
WO2012019106A2 (en) * 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2016025917A1 (en) * 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
JP7071917B2 (ja) 2015-12-09 2022-05-19 カデント セラピューティクス，インコーポレーテッド ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用
US10071988B2 (en) 2016-02-10 2018-09-11 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
CN108713016B (zh) 2016-02-18 2021-10-08 先正达参股股份有限公司 杀有害生物活性吡唑衍生物
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
AR115905A1 (es) 2018-08-03 2021-03-10 Cadent Therapeutics Inc 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda
CA3143103A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyridine carbamates and their use as glun2b receptor modulators
BR112021025141A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
CN114008052A (zh) 2019-06-14 2022-02-01 詹森药业有限公司 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
MX2021015511A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
AU2020293642A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
TW202112774A (zh) 2019-06-14 2021-04-01 比利時商健生藥品公司 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
CN1131031C (zh) 1996-03-08 2003-12-17 弗·哈夫曼-拉罗切有限公司 作为nmda受体亚型阻断剂的4－苯基3，6－二氢－2h－吡啶基衍生物的应用
CA2220649C (en) 1996-12-03 2007-02-13 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
US6015824A (en) 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
ATE257827T1 (de) * 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
ATE274494T1 (de) 2000-04-20 2004-09-15 Hoffmann La Roche Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
US6432985B2 (en) 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
US7022882B2 (en) 2000-10-06 2006-04-04 The Regents Of The University Of California NMDA receptor channel blocker with neuroprotective activity
CA2381630A1 (en) 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
DE10120159A1 (de) 2001-04-25 2002-10-31 Merck Patent Gmbh NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives

Also Published As

Publication number Publication date
TNSN04224A1 (fr) 2007-03-12
CY1105159T1 (el) 2009-11-04
MXPA04011253A (es) 2005-01-25
IL164922A (en) 2012-01-31
HRP20041060B1 (en) 2012-11-30
RU2317294C2 (ru) 2008-02-20
CN1653062A (zh) 2005-08-10
DK1506190T3 (da) 2006-10-16
KR100632868B1 (ko) 2006-10-13
NZ536310A (en) 2007-08-31
CL2004001251A1 (es) 2005-04-22
NO329605B1 (no) 2010-11-22
IL164922A0 (en) 2005-12-18
AU2003242542B2 (en) 2008-10-16
RS98504A (sr) 2006-12-15
CA2485926A1 (en) 2003-11-27
EP1506190B1 (en) 2006-06-14
EP1506190A1 (en) 2005-02-16
HRP20041060A2 (en) 2005-06-30
US7005432B2 (en) 2006-02-28
MA27117A1 (fr) 2004-12-20
ES2265581T3 (es) 2007-02-16
ATE329912T1 (de) 2006-07-15
HK1080845A1 (en) 2006-05-04
KR20040106558A (ko) 2004-12-17
JP4267569B2 (ja) 2009-05-27
US20030229096A1 (en) 2003-12-11
RU2004136979A (ru) 2005-07-10
MEP76708A (en) 2011-12-20
CA2485926C (en) 2009-11-24
JP2005532326A (ja) 2005-10-27
PT1506190E (pt) 2006-11-30
SI1506190T1 (sl) 2006-10-31
DE60306152T2 (de) 2007-04-26
AU2003242542A1 (en) 2003-12-02
ZA200408789B (en) 2005-12-28
DE60306152D1 (de) 2006-07-27
RS51200B (sr) 2010-12-31
NO20044666L (no) 2004-12-15
AR040010A1 (es) 2005-03-09
CN1312151C (zh) 2007-04-25
WO2003097637A1 (en) 2003-11-27
BR0311177A (pt) 2005-03-15
PL211340B1 (pl) 2012-05-31

Similar Documents

Publication Publication Date Title
HRP20041060B1 (en) (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker
PL379420A1 (pl) Pochodne blokerów receptora angiotensyny II
SI2208727T1 (sl) Diaril etri kot antagonisti opioidnega receptorja
IL198122A0 (en) Triazole derivatives as tachykinin receptor antagonists
AU2002353081A1 (en) Pulsatile release histamine h2 antagonist dosage forms
AU2003257032A1 (en) Antibodies against c3a receptor
PL1636206T3 (pl) Pochodne imidazolu jako antagoniści receptorów glutaminianu
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU2003294449A1 (en) Cannabinoid receptor ligands
GB0226227D0 (en) Receptors
AU2003278403A1 (en) 1-alkylpiperazinyl-pyrrolidin-2, 5-dione derivatives as adrenergic receptor antagonist
GB0215389D0 (en) Receptor
AU2003281525A1 (en) Serotonin receptor
GB0223399D0 (en) Receptors
AU2003240730A1 (en) Morpholinylmethylureas ccr-3 receptor antagonist
GB0321998D0 (en) Receptor
AU2003236673A1 (en) G protein-coupled receptor variants
AUPS283002A0 (en) Receptor
AU2002338040A1 (en) Receptor antagonist
GB0307100D0 (en) Receptor
GB0329104D0 (en) Receptor
AU2002951108A0 (en) Receptor specific ligands
AU2002305947A1 (en) Piperidine-piperazine ligand for neurotransmitter receptors
AU2002329501A1 (en) 4-(1-piperidiny)-butylcarboxamide as d3 dopamine receptor subtype selective ligands

Legal Events

Date Code Title Description
RECP Rectifications of patent specification